|[February 12, 2013]
Targeted Medical Pharma is Assigned Comprehensive Pharmaceutical Billing Patent
LOS ANGELES --(Business Wire)--
Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology
company that develops and distributes prescription medical foods to
physicians and pharmacies, today announced it has been issued patent
number 8370172 from the United States Patent and Trademark Office. This
is the company's seventh patent and relates to a system and method for
electronically submitting medication claims by point-of-care physicians.
The patent officially was issued on February 5, 2013.
"The issuance of this billing patent creates an opportunity for our
company and we anticipate that this patent will help increase our
revenue, spur development, and provide a powerful tool for our
customers," said William Shell, M.D., inventor of the patent, CEO and
chief scientific officer at Targeted Medical Pharma, Inc.
More information on patent number 8370172 can be found by visiting http://bit.ly/TRGMPatent5
or clicking here.
About Targeted Medical Pharma, Inc.
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops prescription medical
foods for the treatment of chronic disease including pain syndromes,
peripheral neuropathy, hypertension, obesity, sleep and cognitive
disorders. The company manufactures ten proprietary prescription only
medical foods, as well as 48 convenience packed kits, which pair a
medical food and branded or generic pharmaceutical. These prescription
medical foods and therapeutic systems are sold to physicians and
pharmacies in the U.S. through the company's subsidiary, Physician
Therapeutics. These proprietary medications represent a novel
approach to the management of certain disease states, focusing on safety
and efficacy without the deleterious side effects of traditional, high
dose prescription drugs. Targeted Medical Pharma also provides
diagnostic testing as well as billing and collection services on behalf
of dispensing physicians.
Forward Looking Statement
This press release regarding patent number 8370172 may
contain forward-looking statements related to Targeted Medical Pharma's
business strategy, outlook, objectives, plans, intentions or goals. The
words "may," "will," "should," "plans," "explores," "expects,"
"anticipates," "continue," "estimate," "project," "intend," and similar
expressions, identify forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, but their absence
does not mean that the statement is not forward-looking. These
statements are not guarantees of future performance and are subject to
certain risks, uncertainties, and assumptions that are difficult to
predict. Actual results could differ materially. Targeted Medical Pharma
expressly disclaim any obligation or undertaking to update or revise any
forward-looking statement contained herein to reflect any change in the
company's expectations with regard thereto or any change in events,
conditions or circumstances upon which any statement is based.
[ Back To Technology News's Homepage ]